Cargando…
P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171558/ http://dx.doi.org/10.1097/01.HS9.0000936192.21618.f2 |
| _version_ | 1785039444585218048 |
|---|---|
| author | Facon, T. Plesner, T. Usmani, S. Kumar, S. Bahlis, N. Hulin, C. Orlowski, R. Nahi, H. Mollee, P. Ramasamy, K. Roussel, M. Jaccard, A. Delforge, M. Karlin, L. Arnulf, B. Chari, A. Pei, H. Gupta, N. Kaila, S. Matt, K. Gries, K. Carson, R. Borgsten, F. Weisel, K. Perrot, A. |
| author_facet | Facon, T. Plesner, T. Usmani, S. Kumar, S. Bahlis, N. Hulin, C. Orlowski, R. Nahi, H. Mollee, P. Ramasamy, K. Roussel, M. Jaccard, A. Delforge, M. Karlin, L. Arnulf, B. Chari, A. Pei, H. Gupta, N. Kaila, S. Matt, K. Gries, K. Carson, R. Borgsten, F. Weisel, K. Perrot, A. |
| author_sort | Facon, T. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171558 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101715582023-05-11 P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL Facon, T. Plesner, T. Usmani, S. Kumar, S. Bahlis, N. Hulin, C. Orlowski, R. Nahi, H. Mollee, P. Ramasamy, K. Roussel, M. Jaccard, A. Delforge, M. Karlin, L. Arnulf, B. Chari, A. Pei, H. Gupta, N. Kaila, S. Matt, K. Gries, K. Carson, R. Borgsten, F. Weisel, K. Perrot, A. Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171558/ http://dx.doi.org/10.1097/01.HS9.0000936192.21618.f2 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Facon, T. Plesner, T. Usmani, S. Kumar, S. Bahlis, N. Hulin, C. Orlowski, R. Nahi, H. Mollee, P. Ramasamy, K. Roussel, M. Jaccard, A. Delforge, M. Karlin, L. Arnulf, B. Chari, A. Pei, H. Gupta, N. Kaila, S. Matt, K. Gries, K. Carson, R. Borgsten, F. Weisel, K. Perrot, A. P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL |
| title | P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL |
| title_full | P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL |
| title_fullStr | P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL |
| title_full_unstemmed | P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL |
| title_short | P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL |
| title_sort | p16 health-related quality of life for frail transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone: subgroup analysis of maia trial |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171558/ http://dx.doi.org/10.1097/01.HS9.0000936192.21618.f2 |
| work_keys_str_mv | AT facont p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT plesnert p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT usmanis p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT kumars p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT bahlisn p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT hulinc p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT orlowskir p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT nahih p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT molleep p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT ramasamyk p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT rousselm p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT jaccarda p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT delforgem p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT karlinl p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT arnulfb p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT charia p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT peih p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT guptan p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT kailas p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT mattk p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT griesk p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT carsonr p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT borgstenf p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT weiselk p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial AT perrota p16healthrelatedqualityoflifeforfrailtransplantineligiblepatientswithnewlydiagnosedmultiplemyelomatreatedwithdaratumumablenalidomideanddexamethasonesubgroupanalysisofmaiatrial |